Sector News

Fresenius' $4.3B buyout of Akorn threatened by data integrity probe

March 1, 2018
Life sciences

Fresenius and Akorn say they are investigating whether Akorn violated FDA drug development standards, and that the results of the probe could scuttle the German’s drugmaker’s $4.3 billion deal to buy the U.S. generics maker.

In a statement late Monday, Akorn said the two companies, with the help of of outside consultants, are investigating “alleged breaches of FDA data integrity requirements relating to product development.” It said so far the investigation hasn’t found anything that would affect Akorn finances materially and that it “does not believe this investigation should affect the closing of the transaction with Fresenius.”

But in its own statement Frensenius said that its board would evaluate the results of the probe and “the transaction may be affected if the closing conditions under the merger agreement are not met.”

Both companies said there would be no further updates about the matter, but then, Reuters reported, CEO Stephan Sturm was more pointed in a press conference today saying, “If the allegations prove to be conclusive and are so material that they would impact our targets, then we will withdraw from the contract.”

The disclosures came as Fresenius today reported Q4 sales that were up 8% in constant currencies to €4.4 billion ($5.4 billion). It reported that sales in North America, where it faces “headwinds,” were up 8% to €3.1 billion in Q4. Fresenius said it expects adjusted group sales to grow between 5% and 8% in 2018.

The German drugmaker last year agreed to buy Akorn to expand its Fresenius Kabi sterile manufacturing capacity. It would get three U.S. plants and one in India in the Akorn deal, which was slated to close in early 2018.

Sterile injectables, which is Fresenius’ emphasis, accounted for about 35% of Akorn’s $1.1 billion in sales last year, but analysts also liked that Fresenius was additionally acquiring some new segments like ophthalmics and topical solutions, which might be less vulnerable to the generics pricing pressure that has made life difficult for generics producers in the last few years.

However, FDA concerns about Akorn’s manufacturing capabilities surfaced even before the companies announced the potential for drug development violations. The FDA last spring issued a Form 483 to Akorn’s sterile manufacturing plant in Decatur, Illinois. While it contained only three observations, the issues followed an inspection the year before when nearly a dozen problems were noted.

In one observation, an inspector reported that the company released products even after it was pointed out to Akorn’s VP of domestic sterile products quality assurance that particles that might contaminate injectables appeared to be shedding from a conveyor belt. The inspector noted that the plant had produced 88 lots on that line since it was was set up in that configuration.

Akorn’s India plant has also been on am import alert, banning its products from the U.S., since 2015.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.